CA2837174A1 - Cb-183,315 compositions and related methods - Google Patents
Cb-183,315 compositions and related methods Download PDFInfo
- Publication number
- CA2837174A1 CA2837174A1 CA2837174A CA2837174A CA2837174A1 CA 2837174 A1 CA2837174 A1 CA 2837174A1 CA 2837174 A CA2837174 A CA 2837174A CA 2837174 A CA2837174 A CA 2837174A CA 2837174 A1 CA2837174 A1 CA 2837174A1
- Authority
- CA
- Canada
- Prior art keywords
- sucrose
- solid
- weight percent
- formulations
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490584P | 2011-05-26 | 2011-05-26 | |
| US61/490,584 | 2011-05-26 | ||
| PCT/US2012/039476 WO2012162567A1 (en) | 2011-05-26 | 2012-05-24 | Cb-183,315 compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2837174A1 true CA2837174A1 (en) | 2012-11-29 |
Family
ID=46208839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2837174A Abandoned CA2837174A1 (en) | 2011-05-26 | 2012-05-24 | Cb-183,315 compositions and related methods |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20130109633A1 (https=) |
| EP (1) | EP2714012A1 (https=) |
| JP (1) | JP2014515371A (https=) |
| KR (1) | KR20140037877A (https=) |
| CN (1) | CN103687589A (https=) |
| AR (1) | AR086576A1 (https=) |
| BR (1) | BR112013030369A2 (https=) |
| CA (1) | CA2837174A1 (https=) |
| MX (1) | MX2013013760A (https=) |
| RU (1) | RU2013157188A (https=) |
| TW (1) | TW201300124A (https=) |
| WO (1) | WO2012162567A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109476704B (zh) * | 2016-04-08 | 2022-08-16 | 港大科桥有限公司 | 抗菌环脂肽 |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2394313A1 (en) * | 1999-12-15 | 2001-06-21 | Cubist Pharmaceuticals, Inc. | Novel lipopeptides as antibacterial agents |
| BR0112393A (pt) * | 2000-06-21 | 2003-07-08 | Internat Health Man Associates | Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais |
| NZ554405A (en) * | 2000-12-18 | 2009-04-30 | Cubist Pharm Inc | Method for preparing crystalline and crystal-like forms of purified lipopeptides |
| CA2587848A1 (en) * | 2004-11-12 | 2006-10-19 | Cubist Pharmaceuticals, Inc. | Antiinfective lipopeptides |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| PL2379580T3 (pl) * | 2008-12-22 | 2014-05-30 | Merck Sharp & Dohme | Nowe środki przeciwbakteryjne do leczenia zakażeń wywołanych bakteriami Gram-dodatnimi |
| JP5491119B2 (ja) * | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| CN102060914B (zh) * | 2009-11-13 | 2014-09-17 | 华东理工大学 | 海洋芽孢杆菌b-9987产脂肽类化合物及其制备和应用 |
| JP2013511522A (ja) * | 2009-11-23 | 2013-04-04 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ダプトマイシン製剤 |
| SG10201407724YA (en) * | 2009-11-23 | 2014-12-30 | Cubist Pharm Inc | Daptomycin compositions and related methods |
-
2012
- 2012-05-24 MX MX2013013760A patent/MX2013013760A/es unknown
- 2012-05-24 CN CN201280025551.2A patent/CN103687589A/zh active Pending
- 2012-05-24 WO PCT/US2012/039476 patent/WO2012162567A1/en not_active Ceased
- 2012-05-24 JP JP2014512126A patent/JP2014515371A/ja active Pending
- 2012-05-24 BR BR112013030369A patent/BR112013030369A2/pt not_active IP Right Cessation
- 2012-05-24 KR KR1020137033768A patent/KR20140037877A/ko not_active Withdrawn
- 2012-05-24 CA CA2837174A patent/CA2837174A1/en not_active Abandoned
- 2012-05-24 EP EP12725988.5A patent/EP2714012A1/en not_active Withdrawn
- 2012-05-24 RU RU2013157188/15A patent/RU2013157188A/ru not_active Application Discontinuation
- 2012-05-25 TW TW101118841A patent/TW201300124A/zh unknown
- 2012-05-25 US US13/481,009 patent/US20130109633A1/en not_active Abandoned
- 2012-05-28 AR ARP120101868A patent/AR086576A1/es unknown
-
2013
- 2013-10-07 US US14/047,701 patent/US20140135273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012162567A1 (en) | 2012-11-29 |
| JP2014515371A (ja) | 2014-06-30 |
| BR112013030369A2 (pt) | 2016-12-13 |
| EP2714012A1 (en) | 2014-04-09 |
| MX2013013760A (es) | 2014-01-08 |
| RU2013157188A (ru) | 2015-07-10 |
| US20130109633A1 (en) | 2013-05-02 |
| CN103687589A (zh) | 2014-03-26 |
| TW201300124A (zh) | 2013-01-01 |
| KR20140037877A (ko) | 2014-03-27 |
| US20140135273A1 (en) | 2014-05-15 |
| AR086576A1 (es) | 2014-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK167171B1 (da) | Fremgangsmaade til fremstilling af et stabilt nicorandilholdigt farmaceutisk praeparat | |
| US20090281136A1 (en) | Prasugrel pharmaceutical formulations | |
| US20190008774A1 (en) | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same | |
| RU2713428C1 (ru) | Частицы, содержащие аморфный эмпаглифлозин, способ их получения и содержащий их лекарственный препарат | |
| CN100446757C (zh) | 未经制粒制备的包含阿伐他汀的药物组合物 | |
| KR20100015764A (ko) | 프레가발린을 포함하는 안정한 약학적 조성물 | |
| EP4025192B1 (en) | Process for producing a tablet comprising glp-1 peptides | |
| CN101721410B (zh) | 硫酸氢氯吡格雷的固体药物组合物 | |
| US20090292016A1 (en) | Stable Pharmaceutical Compositions Containing Pravastatin | |
| KR100760112B1 (ko) | 아토르바스타틴의 제약 조성물 | |
| US20140135273A1 (en) | Cb-183,314 compositions and related methods | |
| EP1849830A1 (en) | Finely divided composition containing poorly water soluble substance | |
| EA023996B1 (ru) | Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацевтически приемлемые соли совместно с органической кислотой | |
| EP4436554A1 (en) | Pharmaceutical compositions comprising eltrombopag | |
| KR101441450B1 (ko) | 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도 | |
| JP2020090471A (ja) | アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法 | |
| EP2906203B1 (en) | Effervescent cefdinir formulation | |
| US10272131B2 (en) | Linaclotide stable composition | |
| JP2022130003A (ja) | 漢方エキス又は植物性生薬エキスを含む固形製剤及びその製造方法、並びに固形製剤の崩壊性を向上させる方法 | |
| JP2020090470A (ja) | アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法 | |
| Kolli et al. | Formulation and evaluation of matrix tablet of ramipril | |
| CN101460191A (zh) | 包含湿敏性药物的稳定制剂及其制备方法 | |
| TR202100250A2 (tr) | Api̇ksaban i̇çeren fi̇lm kapli tablet | |
| TR201711422A2 (tr) | Valsartan ve klortali̇don i̇çeren farmasöti̇k bi̇leşi̇m | |
| GB2491205A (en) | Composition comprising bosentan and diluents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20180524 |